TUESDAY, SEPTEMBER 20
8:00AM – 5:00PM
Registration
8:00AM – 8:45AM
Morning Coffee Networking
8:45AM – 9:00AM
Chairperson’s Welcome
Speaker: Rebecca Willumson | Publisher | FierceBiotech
9:00AM – 9:50AM
KEYNOTE | Shire: Driving Growth by Building the Global Leader in Rare Diseases and Highly Specialized Conditions
Shire is striving for leadership positions in multiple, high-value franchises and to become the clear partner of choice in rare diseases and highly specialized conditions. 2015 saw the acquisition of NPS Pharmaceuticals and Dyax along with the integration of ViroPharma. 2016 was truly transformative for the Company following the successful combination with Baxalta earlier this year and the FDA approval of ophthalmics drug Xiidra.
The Baxalta deal gives Shire an impressive pipeline, with franchise operations that extend from hematology to immunology, neuroscience, lysosomal storage disorders and more. The combined company will generate 65% of its revenue from drugs that target rare diseases by 2020. Hear how Shire’s R&D head plans to forge strategic research collaborations and partnerships while reinvesting in targeted and innovative in-house R&D to drive its pipeline forward.
Phil Vickers | Global Head of Research & Development | Shire Pharmaceuticals
10:00AM – 10:50AM
GENERAL SESSION: Biotech IPOs in 2017
Moderator: Kimberly Ha | Senior Director, Strategic Communications | FTI Consulting
Panelists:
Bruce Booth | Partner | Atlas Venture
Wende Hutton | General Partner | Canaan
Dr. Carol Gallagher, PharmD | Partner | NEA
Simos Simeonidis, PhD | Managing Director – US Biotechnology Equity Research | RBC Capital Markets
Brian Hagerty | Senior Director, Head of Healthcare Capital Markets | New York Stock Exchange
It’s no secret that IPOs have been chilled by the bear market that ravaged biotech stock prices in Q1—but they weren’t eliminated from the scene. Our panel of IPO experts will size up the current market and look at the prospects for 2017. What are the factors that will determine a solid IPO? And when should companies stay away from an S-1?
10:50AM – 11:10AM
Networking & Refreshment Break
11:10AM – 12:00PM
R&D: Phase I/IIa: Early-stage Strategies and Phase III: The Pivotal Moment
Moderator: Amirah Al Idrus | Editor | FierceBiotech
Panelists:
Barry Ticho MD, PhD | Head of Development CVMD | Moderna Therapeutics
Susan Washer | CEO | Applied Genetic Technologies Corporation
Jim Roach MD, FACP, FCCP | SVP – Development and Chief Medical Officer | Momenta Pharmaceuticals, Inc.
Beatrice Setnik | Vice President of Clinical Pharmacology | INC Research
The standard trial path for drugs has been revolutionized in the past decade. These days, most developers design an early-stage program that can establish safety AND proof-of-concept data at an early stage. Recruit the right number of the right patients, and you can enhance your chances of getting the right partner for a pivotal program. In this session, experts will look at the impact of new technologies and FDA guidances on early-stage studies.
With the right late-stage development program, it’s possible to cut years out of a clinical pathway to an approval. The FDA has been helping with its new breakthrough program, just the latest in several agency designations aimed at speeding up approvals. And biopharma has responded with aggressive studies that can pinpoint the right surrogate endpoints and identify early signs of efficacy that can be further confirmed in post-marketing studies.
P&D: BioPharma M&A
Moderator: Carly Helfand | Senior Editor | FiercePharma & FiercePharmaMarketing
Panelists:
Mark G. Barrett | Vice President, Global Head of Strategy & Business Development | Genzyme
Luba Greenwood | Vice President, Global Business Development and Mergers & Acquisitions | Roche
Samantha Truex | Former CBO | Padlock Therapeutics
Alan Butcher | Head of Licensing & Business Development | Purdue Pharma
All the fundamentals are in place for a vibrant M&A market. But, Big Pharma still needs new assets for variable pipelines after years of weak productivity, yet Big Pharma CEOs have been leery about the prices they’re asked to pay. M&A advisers will discuss the art of the deal, and what lies ahead in deal terms.
C&O: New Tools for Patient Recruitment
Moderator: Beth Snyder Bulik | Contributing Writer | FiercePharmaMarketing
Panelists:
John Lewis | SVP – Policy & Public Affairs | Association of Clinical Research Organizations
Nathan Sanburn | Regional Director Medical-East Oncology, US Medical Affairs | Eli Lilly & Co.
Paulo Moreira | Vice President – Global Clinical Operations | EMD Serono
Matthew Howes | Executive Vice President, Strategy & Growth | PALIO, an inVentiv Health Company
Everyday new tools are being introduced to help companies identify, screen, and recruit patients in clinical trials. New mobile apps and social media networks like Facebook have helped revolutionize the way patients are recruited for clinical trials. The objective of using these approaches and tools is to expedite recruitment of eligible patients. Find out what’s new, and how it might help you.
12:00 PM – 1:00PM
Lunch & Sponsor Networking
1:00PM – 1:50PM
GENERAL SESSION: The Genomics Package
Moderator: Stacy Lawrence | Editor-in-Chief | FierceBiotech
Panelists:
Alex Parker, PhD | Vice President, Business Development | Foundation Medicine
Issi Rozen | Chief Business Officer | Broad Institute of MIT and Harvard
Murray Robinson, PhD | President | Molquant, Inc.
JC Gutierrez-Ramos | CEO | Synlogic
How are drugmakers working with top sequencing centers and companies? This session will take a look at accomplishments and challenges, with panelists from genomics institutes and drugmakers that are using their data in drug development. How will genomics change the way drugs are identified and developed? And how can small companies take advantage?
2:00PM – 2:50PM
R&D: Fine Tuning Remote Patient Monitoring in Clinical Trials
Moderator: Stacy Lawrence | Editor-in-Chief | FierceBiotech
Panelists:
Fred Cox | Senior Director – Patient Outcomes and Medical Economics | Sanofi Genzyme
Yury Rozenman | Director of Business Development | Qualcomm Life
David Van Sickle | Co-Founder & CEO | Propeller Health
Jane Rhodes | Senior Director – New Initiatives & Innovation Hub | Biogen
How are pharma companies using new monitoring technologies to generate trial data? Smart inhalers from a variety of respiratory developers, plus other testing and communications devices can keep track of adherence and patient results for real-time monitoring during clinical studies. What are the advantages and disadvantages of remote monitoring? Is it cost-effective? Find out the answers to these questions and more during this informative session.
P&D: Partnerships in Immuno-Oncology
Moderator: Arlene Weintraub | Contributing Writer | FierceBiotech
Panelists:
David Sherris PhD | President & CEO | GenAdam Therapeutics, Inc.
Steven Tregay, PhD | President & CEO | Forma Therapeutics
Anne Altmeyer | VP – Business Development | Shire Pharmaceuticals
Jeff Albers | President & CEO | Blueprint Medicines
Etienne Drouet | Vice President Strategic Development | SynteractHCR
Immunotherapies for cancer are among the hottest drug candidates out there, and this trend has inspired a frenzy of collaborations among biotechs and pharma. In some cases, developers have begun to identify and pursue second-generation approaches before the first generation has even hit the market. How is this field likely to develop over the next 5 years, and what kind of natural boundaries will form as the leaders stake their claims to a share of a multibillion-dollar market?
C&O: Taking Maximum Advantage of Rare/Orphan Disease R&D Edge
Moderator: Markus Peters | Associate Partner | Alacrita
Panelists:
Stacy Coen | Head of Rare Disease Business Development & Licensing | Sanofi Genzyme
John Orloff | Biopharma R&D Executive
Mark Baglin | VP – Product Strategy | Shire Pharmaceuticals
Jeremy Springhorn | Partner – Corporate Development | Flagship Ventures
Karen Kaucic, MD | Vice President, Global Head | PPD® Consulting
One ideal approach in biotech is pursuing a new drug for rare/orphan diseases. Trials can be smaller and more affordable. It’s more realistic to blue print a marketing campaign. And Big Biopharma companies are ready and willing to buy in when the data is right. Our experts review some case studies on how this can be done right, and where the pitfalls are.
3:00PM – 3:50PM
R&D: Translational R&D Transformation
Moderator: Arlene Weintraub | Contributing Writer | FierceBiotech
Panelists:
Kenneth Kaitin, PhD | Professor & Director | Tuft Center for the Study of Drug Development / Tufts University School of Medicine
Lloyd Klickstein MD, PhD | Head of Translational Medicine, NIDU | Novartis Institutes for BioMedical Research, Inc.
Michael Kauffman | CEO | Karyopharm
John Quisel | SVP – Business Development and General Counsel | Acceleron
Harvard’s recent $20 million deal to out-license a preclinical drug to Merck & Co. underscores the transformation underway in translation research. While venture capital groups had already been cherry-picking some of the best academic research for the IP used to launch new companies, many academic investigators are now going the extra mile in candidate selection to enhance the value of their work, making it clinic-ready for development teams. How will this trend shape the next wave of new drug programs and upstart biotechs?
P&D: Early Research Analytics to Drive Precision Medicine and Increase PTRS
Speaker: Mike Mentasana | Pharmaceutical & Life Sciences R&D Advisory Leader, Partner | PwC
We are at the beginning of a “New Frontier” in biopharma research and development where advanced analytics are embedded into the discovery and development of products tailored to specific patient characteristics with increasing precision. The exponential growth in the volume and variety of medical information combined with recent advances in data storage and computing technology provide an incredibly rich data source and a cost-effective way to analyze it. Today, scientists across the industry are beginning to use these novel techniques to generate new insights about patients and underlying disease biology. Our panel of experts will discuss practical applications of advanced analytics being used today and share their vision for the future.
C&O: Innovative Drug Delivery Technologies
Moderator: Cornell Stamoran, Ph.D. | Vice President, Strategy | Catalent, Inc. | Founder and Co-Chair | Catalent Applied Drug Delivery Institute
Panelists:
Menashe Y. Levy PhD | VP & Chief Technology Officer – Global R&D | Teva
Ronald L. Smith | Scientific AVP – Pharmaceutical Sciences | Merck Research Laboratories
Keith Horspool | VP – Pharmaceutics | Boehringer Ingelheim
Robert Walsh, MD | Medical Director – Pharmacovigilance & Patient Safety | AbbVie
Better delivery can extend patent control and offer a new lease on life for many older drugs. These technologies are also key to hitting once undruggable targets. Learn what you need to know, now, in this informative session.
4:00PM – 5:00PM
GENERAL SESSION: 2016 Top Women in Biotech Panel
Moderator: Tracy Staton | Editor-in-Chief | FiercePharma
Panelists:
Anna Protopapas | President & CEO | Mersana Therapeutics
Cynthia Verst, PharmD | MS President – Clinical Operations | Quintiles
Susan B. Dillon, PhD | Global Therapeutic Area Head – Immunology Janssen Research & Development | Johnson & Johnson
Kathrin Jansen PhD | SVP & Head of Vaccine Research & Development | Pfizer
Over the past decade a group of extraordinary women has put the well-worn cliché that men dominate the top ranks of the biotech industry to the test! Along the way, they’ve learned some very important lessons. Join these top-notch women in the industry address the challenges they’ve faced in their careers and suggest ways companies can recruit talented women and create a working environment that’s friendlier to them.
5:00PM – 6:30PM
2016 Top Women in Biopharma Awards Presentation & Networking Reception
It’s a well-worn cliché that men dominate the top ranks of the biotech industry. But over the past decade a group of extraordinary women has put that cliché to the test. For each of the honorees, there are unique stories about how impressive women have gotten ahead in the competitive biotech field. The FierceBiotech Top Women in Biopharma is a celebration of women in the life sciences industry, academia and regulatory roles who are outstanding members of the field.